Navigation Links
Anthera Pharmaceuticals to Present at Deutsche Bank Securities' 35th Annual Health Care Conference
Date:4/26/2010

HAYWARD, Calif., April 26 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced Paul F. Truex, Anthera's President and Chief Executive Officer will present at the Deutsche Bank 35th Annual Health Care Conference in Boston, MA on Monday, May 3, 2010 at approximately 9:20 am Eastern Time.  

To access live audio broadcasts of these presentations, or the subsequent archived recordings, log onto http://www.anthera.com.  Please connect to the website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.  

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 ready clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases suc
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
2. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
3. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
5. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
8. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
9. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
11. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3, 2015  VirtualScopics, Inc. (NASDAQ: ... trial imaging solutions, announced today, they are collaborating ... a new philanthropic, epidemiology study partnering with the ... .  VirtualScopics has teamed up with a cardiac ... The image results will be used to identify ...
(Date:9/3/2015)... 2015  Omeros Corporation (NASDAQ: OMER ) today ... Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, ... the District of New Jersey ... of Delaware . The lawsuits were ... three Omeros patents, U.S. Patent Nos. 8,173,707, 8,586,633 and ...
(Date:9/3/2015)... Sept. 3, 2015 Research and Markets ... the "Investigation Report on China Tamsulosin Market, ... Compared with other a1- adrenergic receptor blockers, ... and lower risk of urinary tract infections and ... its debut in 1993 in Japan ...
Breaking Medicine Technology:VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 2VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 3VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 4Omeros Files Infringement Suits Against Par 2Omeros Files Infringement Suits Against Par 3Omeros Files Infringement Suits Against Par 4China Tamsulosin Market Investigation Report 2015 2
... 16, 2011 HYCOR Biomedical, Inc., a leading manufacturer and ... autoimmune and urinalysis markets, together with owner Linden, LLC, today ... Ph.D., to its Board of Directors as part of its ... welcome Drs. Aggarwal and Koziarz to the HYCOR team and ...
... May 16, 2011 Echo Therapeutics, ... tCGM System as a non-invasive, wireless, transdermal continuous ... System for transdermal drug delivery, today announced that ... its Chief Financial Officer.  Mr. Schnittker is a ...
Cached Medicine Technology:HYCOR Expands Board of Directors to Support Growth in Key Areas 2Echo Therapeutics Appoints Christopher P. Schnittker as Chief Financial Officer 2Echo Therapeutics Appoints Christopher P. Schnittker as Chief Financial Officer 3
(Date:9/3/2015)... ... September 03, 2015 , ... Dr. Robert Winchell has been appointed director of ... Care at NewYork-Presbyterian/Weill Cornell Medical Center, effective July 27. He will serve on the ... in care for the critically injured and the development, design and operations of trauma ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... Global ... announced that it will be spotlighting its award-winning print and artwork inspection solutions, ... team September 16 and 17 at the Olympia London, booth #F33 , Be the ...
(Date:9/3/2015)... ... September 03, 2015 , ... Atlantic Information Services, ... “Proven Pharmacy Benefit Strategies for a Rapidly Changing Marketplace.” In this Sept. 16 ... Milliman, will discuss how plan sponsors are adopting bold, innovative strategies to control ...
(Date:9/3/2015)... TEXAS (PRWEB) , ... September 03, 2015 , ... ... the Lone Survivor Foundation with a champion AKC Black Lab Puppy. Celebrate Fall 2015 ... canine companion, for friends and family to enjoy Thanksgiving and Christmas with an extra ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ProScrub is ... create back & forth, flicker, repeat, and custom speed effects without the use of ... the speed of effect. ProScrub tools are perfect complements to energetic video productions. ...
Breaking Medicine News(10 mins):Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Speakers for Upcoming AIS Virtual Conference on Pharmacy Benefit Strategies Include Executives from CVS Health, Express Scripts 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2
... June 6 (HealthDay News) -- Men who have type 2 ... from a regular exercise regimen, a new study has found. ... boost survival rates for men with both conditions, researchers found. ... which commonly occurs in people with diabetes and high blood ...
... A new poll by the Harvard School of Public Health ... the health care reform legislation enacted in 2006, 21% oppose ... heard or read about the law. The percentage of residents ... Support for the law varied by party affiliation, with 77% ...
... Hull have discovered a way to load up nanoparticles ... more effective form of photodynamic therapy (PDT) for treating ... light, cause irreparable damage to cells by creating toxic ... works with individual light-sensitive molecules but the new ...
... CHICAGO As the world marks the 30-year anniversary of ... a new challenge for people with the incurable disease. ... higher rate of cancers not usually associated with HIV. ... and neck, liver, kidney, and anal cancers, among others. ...
... A new targeted therapy for prostate cancer halts tumor ... resistant to hormone therapy, a new study finds. The ... 93rd Annual Meeting in Boston. "This targeted therapy ... lives of men with advanced, hormone-refractory prostate cancer," said ...
... Amanda Gardner HealthDay Reporter , SATURDAY, June 4 ... cancer drug, Avastin, may benefit both early stage ovarian cancer ... both studies, presented Saturday at the annual meeting of the ... added to standard chemotherapy. But the high cost ...
Cached Medicine News:Health News:Exercise Helps Men Battling Diabetes and Sleep Apnea 2Health News:Support for Massachusetts landmark health reform law rises in 2011 2Health News:Support for Massachusetts landmark health reform law rises in 2011 3Health News:Research creates nanoparticles perfectly formed to tackle cancer 2Health News:Many of those living with HIV face a new life-threatening challenge: cancer 2Health News:Many of those living with HIV face a new life-threatening challenge: cancer 3Health News:Targeted cancer therapy kills prostate tumor cells 2Health News:Cancer Drug Avastin Makes Inroads Against Ovarian Tumors 2Health News:Cancer Drug Avastin Makes Inroads Against Ovarian Tumors 3
KIMBERLY-CLARK BALLARD Neonatal and Pediatric TRACH CARE Y features lavage/irrigation port and locking thumb port. Multiple French sizes and packaging configurations. Gamma sterilized....
... tubes include an obturator, ... disconnect wedge, cleaning brush, ... inner cannulae., ,Uncuffed ... Velcro® trach tube holder, ...
... patients with obstructive sleep apnea necessitating tracheotomy, ... support. Also indicated where airway access for ... ,Another excellent choice for a sleep ... tube series. Available with a low profile ...
Fenestrations allow your patients to vocalize when cuff is deflated...
Medicine Products: